4.7 Article

Rare Copy Number Variants in Tourette Syndrome Disrupt Genes in Histaminergic Pathways and Overlap with Autism

Journal

BIOLOGICAL PSYCHIATRY
Volume 71, Issue 5, Pages 392-402

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2011.09.034

Keywords

Autism; CNV; copy number variation; GABA; histamine; Tourette syndrome

Funding

  1. National Institutes of Health (NIH) [R01MH092289, R01MH092293, R01MH092520, R01NS056276, R01MH061940, K05MH076273, R25MH077823, UL1RR024139, U24NS051869]
  2. Shepherd Foundation
  3. Overlook International Fund
  4. Yale Program on Neurogenetics
  5. New Jersey Center for Tourette Syndrome & Associated Disorders through New Jersey Department of Health and Senior Services [09-1839-FS-N-0]
  6. Tourette Syndrome Association
  7. Talecris Biotherapeutics
  8. Klingenstein Third Generation Foundation
  9. Psyadon Pharmaceuticals
  10. NIH (National Institute of Mental Health) [R01 MH078160, R01 MH08185]
  11. NIH (National Institute for Neurological Disease and Stroke) [NS056276]
  12. Cincinnati Children's Hospital Research Foundation
  13. University of Cincinnati
  14. Netherlands Organization for Scientific Research
  15. Netherlands Organization for Health Research and Development
  16. European Science Foundations
  17. Otsuka Pharmaceuticals

Ask authors/readers for more resources

Background: Studies of copy number variation (CNV) have characterized loci and molecular pathways in a range of neuropsychiatric conditions. We analyzed rare CNVs in Tourette syndrome (TS) to identify novel risk regions and relevant pathways, to evaluate burden of structural variation in cases versus controls, and to assess overlap of identified variations with those in other neuropsychiatric syndromes. Methods: We conducted a case-control study of 460 individuals with TS, including 148 parent-child trios and 1131 controls. CNV analysis was undertaken using 370 K to 1 M probe arrays, and genotyping data were used to match cases and controls for ancestry. CNVs present in < 1% of the population were evaluated. Results: While there was no significant increase in the number of de novo or transmitted rare CNVs in cases versus controls, pathway analysis using multiple algorithms showed enrichment of genes within histamine receptor (subtypes 1 and 2) signaling pathways (p = 5.8 x 10(-4) - 1.6 x 10(-2)), as well as axon guidance, cell adhesion, nervous system development, and synaptic structure and function processes. Genes mapping within rare CNVs in TS showed significant overlap with those previously identified in autism spectrum disorders but not intellectual disability or schizophrenia. Three large, likely pathogenic, de novo events were identified, including one disrupting multiple gamma-aminobutyric acid receptor genes. Conclusions: We identify further evidence supporting recent findings regarding the involvement of histaminergic and gamma-aminobutyric acidergic mechanisms in the etiology of TS and show an overlap of rare CNVs in TS and autism spectrum disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available